跳至主要内容

Medicilon assists Insilico Medicine in obtaining approval for MAT2A inhibitor in both China and the United States

 Recently, ISM3412, a class 1 new drug developed by InSilico Medicine Cayman TopCo (Insilico Medicine), received implied approval for clinical trials in China. The indication is for advanced/metastatic solid tumors.  ISM3412 is a highly selective oral MAT2A inhibitor discovered with the assistance of artificial intelligence. It received FDA approval in April 2024 to conduct clinical trials in the United States for the treatment of MTAP- deficient cancers.

As a strategic partner of Insilico Medicine, Medicilon provided preclinical research services for ISM3412, including pharmacokinetics and safety evaluation tests. This support laid a solid foundation for the rapid approval of the drug.

Insilico Medicine.webp

"Synthetic Lethality" New Target MAT2A 
   ISM3412 is expected to become "Best-in-Class"

ISM3412 is a structurally novel and highly selective MAT2A inhibitor, designed with the assistance of Insilico Medicine's generative chemistry engine, Chemistry42, using a ligand-based drug design (LBDD) strategy.  In preclinical studies, ISM3412 demonstrated excellent drug-like properties, strong efficacy at low doses, good solubility and permeability, and ideal safety characteristics in animal models.  Insilico Medicine presented some of the preclinical data from this project at the 2023 AACR conference. These data support further clinical evaluation of ISM3412 as a potential best-in-class MAT2A inhibitor.  In preclinical experiments, ISM3412 demonstrated specific inhibition of MTAP-deleted cancer cells and showed a more favorable safety profile, offering the potential to provide new treatment options for clinical patients.  Furthermore, ISM3412 not only demonstrates potent monotherapy efficacy but also exhibits synergistic "synthetic lethality" when used in combination with PRMT5 inhibitors.

The dual approval of ISM3412 in both the United States and China marks another significant milestone for Insilico Medicine in the field of artificial intelligence-driven pharmaceuticals.  Since 2021, Insilico Medicine has established over 30 diverse in-house pipeline combinations and nominated 18 preclinical candidate projects from them. Among these, 7 projects have successfully progressed to the clinical trial stage.  The achievement fully demonstrates Insilico Medicine's leading position and innovative capabilities in the field of artificial intelligence-driven pharmaceuticals.

Deep Integration of AI and R&D
Medicilon Facilitates Drug Development into a High-Speed Era

The deep integration of AI and pharmaceuticals has enabled Insilico Medicine to achieve the clinical stage entry of 7 projects in just 3 years, providing unprecedented speed and possibilities in drug development.  As an avid supporter of AI pharmaceuticals, Medicilon not only provides preclinical research services including efficacy, pharmacokinetics, and safety evaluation for AI drugs but also has established an AI technology service platform. This platform covers advanced technologies such as protein structure prediction and simulation, binding site discovery, information extraction and cleansing, and customized project database construction. It enables deep involvement in critical stages of drug development, such as Target-to-hit, Hit-to-lead, Lead-to-PCC, facilitating efficient advancement of drug development pipelines.

Medicilon congratulates Insilico Medicine on the dual approval of ISM3412 in both the United States and China, and looks forward to the smooth progress of ISM3412 in clinical trials, bringing new treatment options to patients with advanced/metastatic solid tumors at the earliest opportunity.  Medicilon will continue to innovate and integrate cutting-edge technologies, accelerating the deep integration of AI and drug development. We are committed to providing our clients with customized solutions for "speeding up, reducing costs, and increasing efficiency". We will collaborate closely with partners like Insilico Medicine to advance the development of the AI+ pharmaceutical field together!

About Insilico Medicine

Insilico Medicine is a clinical-stage biotechnology company driven by generative artificial intelligence. Through next-generation AI systems connecting biology, chemistry, and clinical trial analysis, Insilico Medicine utilizes modern machine learning technologies such as deep generative models, reinforcement learning, and transformer models to build a powerful and efficient AI drug development platform. This platform identifies novel targets and generates candidate drugs with specific molecular structures.  Insilico Medicine focuses on areas of unmet medical needs such as cancer, fibrosis, immunology, central nervous system diseases, and age-related diseases, advancing and accelerating the development of innovative drugs.

标签：
地点: 美国

评论

发表评论

此博客中的热门博文

What is preclinical testing?

In the process of  preclinical testing  of a compound or biological agent into a drug, the compound involved must go through the testing phase. First, we need to identify potential targets that can treat the disease. Then, a variety of compounds or preparations are screened out. Any compound that has shown potential as a drug for the treatment of this disease needs to be tested for toxicity before clinical testing to reduce the possibility of injury. preclinical testing What is the basis of preclinical testing? According to US Food and Drug Administration (FDA) regulations, a series of tests are required before a new drug is approved for use. In the first stage, basic research determines a hypothetical target for the treatment of a certain disease, and then screens small molecules or biological compounds to discover any substance with the potential to treat the disease. Then, a  preclinical research  phase followed, before which, as described above, the potential toxicity of the compou
发表评论
阅读全文

Inventory of the three major in vitro pharmacokinetic research methods

  The metabolic properties of a compound are an essential factor in whether or not it can be used as a drug in the clinical setting, so pharmacokinetic studies of newly synthesized compounds are required in drug development. In vitro incubation with liver microsomes, recombinant CYP450 enzyme lines, and in vitro incubation with hepatocytes are some of the more common in vitro drug metabolism methods. 1. In vitro incubation method with liver microsomes The metabolic stability and metabolic phenotypes of candidate compounds in different species of liver microsomes are good predictors of the metabolic properties of compounds in vivo. They are practical tools for evaluating candidate compounds in the pre-development phase of drug development. Liver microsomes include rat liver microsomes, human liver microsomes, canine liver microsomes, monkey liver microsomes, and mouse liver microsomes. In in vitro incubation of the liver, microsomes are the "gold standard" for in vitro d
发表评论
阅读全文

Novel Parkinson’s Therapies Possible with New Mouse Model

Parkinson's disease (PD) is a neurodegenerative disorder that is marked by the accumulation of the protein, α-synuclein (αS), into clumps known as Lewy bodies, which diminish neural health. Now, researchers from Brigham and Women's Hospital (BWH) report the development of a mouse model to induce PD-like αS aggregation, leading to resting tremor and abnormal movement control. The mouse responds to L-DOPA, similarly to patients with PD. The team's study (“Abrogating Native α-Synuclein Tetramers in Mice Causes a L-DOPA-Responsive Motor Syndrome Closely Resembling Parkinson’s Disease”) on the use of this transgenic mouse model appears in  Neuron . “α-Synuclein (αS) regulates vesicle exocytosis but forms insoluble deposits in PD. Developing disease-modifying therapies requires animal models that reproduce cardinal features of PD. We recently described a previously unrecognized physiological form of αS, α-helical tetramers, and showed that familial PD-causing missense mutati
发表评论
阅读全文